IGHE and asthma: This mechanism makes ligelizumab a promising candidate for treating allergic diseases characterized by IgE-mediated inflammation, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), food allergies, and asthma [103].